Triple Antithrombotic Therapy and Outcomes in Post-PCI Patients Undergoing Non-cardiac Surgery
- 308 Downloads
Triple therapy, or the use of anticoagulants with dual antiplatelet therapy (DAPT), is often used to protect against ischemic events in post-percutaneous coronary intervention (PCI) patients with indications for anticoagulation, but is associated with increased bleeding. As both ischemic and bleeding risks increase in the perioperative period, the impact of triple therapy may be especially pronounced in patients undergoing surgery. Outcomes in this population are currently unknown.
We identified patients undergoing non-cardiac surgeries within 2 years of PCI in Veterans Affairs hospitals from 2004 to 2012. We compared perioperative major adverse cardiovascular and cerebrovascular events (MACCE: mortality, myocardial infarction, stroke, revascularization) and bleeding events (in-hospital bleeding, transfusion) between surgeries in patients prescribed triple therapy and DAPT, adjusting for clinical, demographic, and operative characteristics.
Among 7811 surgeries, 391 (5.0 %) occurred in patients receiving triple therapy. 44 (11.3 %) MACCE and 107 (27.4 %) bleeding events occurred with surgeries in triple therapy patients, compared to 366 (4.9 %) MACCE and 980 (13.2 %) bleeding events in DAPT patients. After adjustment, surgery in triple therapy patients was associated with higher rates of MACCE [odds ratio (OR) 1.65, 95 % confidence interval (CI) 1.16–2.34] or bleeding (OR 1.52, 95 % CI 1.17–1.99) as compared to surgery in DAPT patients.
One in twenty post-PCI patients undergoing non-cardiac surgery were on triple therapy. Surgery in these patients was associated with higher MACCE and bleeding events compared to surgery in patients on DAPT, independent of clinical and operative characteristics. These findings identify a high-risk population for surgery, which may warrant increased surveillance for adverse perioperative events.
KeywordsClopidogrel Triple Therapy Bleeding Event Prasugrel Ticagrelor
There are no relationships with industry to disclose. Dr. Valle is supported by a NIH T32 training Grant HL0782 at the University of Colorado, Aurora, CO.
- 1.Ruiz-Nodar JM, Marin F, Hurtado JA et al (2008) Anticoagulant and antiplatelet therapy use in 426 patients with atrial fibrillation undergoing percutaneous coronary intervention and stent implantation implications for bleeding risk and prognosis. J Am Coll Cardiol 51:818–825CrossRefPubMedGoogle Scholar
- 5.Lamberts M, Olesen JB, Ruwald MH et al (2012) Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study. Circulation 126:1185–1193CrossRefPubMedGoogle Scholar
- 6.Nikolsky E, Mehran R, Dangas GD et al (2012) Outcomes of patients treated with triple antithrombotic therapy after primary percutaneous coronary intervention for ST-elevation myocardial infarction (from the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction [HORIZONS-AMI] trial). Am J Cardiol 109:831–838CrossRefPubMedGoogle Scholar
- 11.January CT, Wann LS, Alpert JS et al (2014) AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation 130:2071–2104CrossRefPubMedGoogle Scholar
- 12.Lip GY, Windecker S, Huber K et al (2014) Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS). Eur Heart J 35:3155–3179CrossRefPubMedGoogle Scholar
- 17.Lazio BE, Simard JM. Anticoagulation in neurosurgical patients. Neurosurgery 1999;45:838-47; discussion 847-8Google Scholar
- 22.Perrin R, Bates J, Noel PH, Copeland LA, Lancaster B (2008) National clinical data for VA research: the VA corporate data warehouse. In: HSR&D national meeting, Baltimore, MD. Department of Veterans Affairs, Washington, DCGoogle Scholar
- 32.Naidu SS, Krucoff MW, Rutledge DR et al (2012) Contemporary incidence and predictors of stent thrombosis and other major adverse cardiac events in the year after XIENCE V implantation: results from the 8061-patient XIENCE V United States study. JACC Cardiovascular interventions 5:626–635CrossRefPubMedGoogle Scholar
- 33.Gibson CM, Mehran R, Bode C et al (2015) An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin k antagonist treatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention (PIONEER AF-PCI). Am Heart J 169:472–478.e5CrossRefPubMedGoogle Scholar
- 34.Clinicaltrials.gov. Evaluation of Dual Therapy With Dabigatran vs. Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting (REDUAL-PCI)Google Scholar